AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Myomo, Inc.
Video analysis: MYO
All videosNo video analysis for this stock yet. Request one from our team.
News: MYO
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 at the Lotte Palace Hotel in New York. Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer.
Myomo Q2 Earnings Call Highlights
Myomo NYSEAMERICAN: MYO reported second-quarter 2026 revenue growth of 21% as the wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships.
Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript
Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.11 per share a year ago.
Myomo Reports Second Quarter 2026 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2026. “I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, with 53% of.
Myomo to Report Second Quarter 2026 Financial Results on August 5
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and an.
Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, taking place June 23–24, 2026. President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will deliver a presentati.
Similar companies
-
Modular Medical, Inc.
MODD
·
NASDAQ
Compare
-
Hyperion DeFi, Inc.
HYPD
·
NASDAQ
Compare
-
Vicarious Surgical Inc.
RBOT
·
Other OTC
Compare
-
Precision Optics Corporation, Inc.
POCI
·
NASDAQ
Compare
-
NeuroOne Medical Technologies Corporation
NMTC
·
NASDAQ
Compare
-
MIRA Pharmaceuticals, Inc.
MIRA
·
NASDAQ
Compare